« Return to News | Awards & Advancement

J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

Gorsky, currently vice chairman of J&J’s Executive Committee, succeeds Bill Weldon, who served as CEO since 2002. As CEO, Gorsky will assume full management responsibilities for J&J, including those currently reporting to him and to Weldon.   

Gorsky began his J&J career in 1988 and advanced over the next 15 years through positions of increasing responsibility in sales, marketing, and management. In 2001, he was appointed president of Janssen, and in 2003 he was promoted to company group chairman of J&J’s pharmaceuticals business in Europe, the Middle East and Africa. After a brief stint with Novartis, Gorsky returned to J&J as company group chairman and worldwide franchise chairman for Ethicon in the medical devices business and has been climbing the ladder ever since.

Gorsky was also nominated for election to the board of directors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.